Workflow
AstraZeneca: Consistent Growth And Upcoming Catalysts Make This A Buy (NASDAQ:AZN)
Seeking Alpha· 2025-09-19 13:30
The Cambridge, UK-based AstraZeneca PLC ( AZN ) was founded in 1999 as an amalgamation of the pharmaceutical companies Zeneca Group, based in Britain, and Astra AB, from Sweden. The company’s primary listing is in the UK (I have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believe the key to c ...
IIT placements gain steam; SoftBank's Vision Fund layoffs
The Economic Times· 2025-09-19 13:30
IIT placements gain steam; SoftBank's Vision Fund layoffsWant this newsletter delivered to your inbox?Also in the letter:■ Pepperfry finds new home■ Russians to go cashless in India■ DPDP Act: A timelineHiring momentum builds ahead of IIT placements The placement season at India's top engineering institutes Now hiring: Placements have kicked off at Indian Institutes of Technology (IITs) in Mumbai, Delhi, Madras, Kharagpur, Kanpur, BHU and Roorkee, with upbeat recruiter registrations across the board.Sanjay ...
3 Storage Devices Stocks to Focus on Amid Industry Headwinds
ZACKS· 2025-09-19 13:30
Core Insights - The Zacks Computer-Storage Devices industry faces challenges from escalating trade tensions, macroeconomic turbulence, and intense competition, but benefits from trends like digital transformation, edge computing, and AI workload proliferation [1][2][6] Industry Overview - The industry includes companies that design, develop, manufacture, and market HDDs and SSDs for various devices, with some offering software-defined all-flash solutions and high-performance memory subsystems [3] Trends Influencing Growth - AI is driving demand for high-speed, high-capacity storage solutions, necessitating a shift towards NVMe-based SSDs and object storage for unstructured data [4] - Cloud storage technologies are evolving, with a focus on virtualization and edge computing to manage increasing data complexity and scale [5] Macro Conditions - Trade tensions and inflation are significant concerns, potentially affecting global IT spending, which is projected to reach $5.43 trillion in 2025, a 7.9% increase from 2024 [6] - PC shipments increased by 4.4% year-over-year in Q2 2025, but are expected to plateau in the latter half of the year due to vendor inventory adjustments [7][8] Industry Performance - The Zacks Computer-Storage Devices industry has outperformed the S&P 500 with a 22.7% increase over the past year, compared to the S&P 500's 17.8% gain, but lags behind the broader sector's 28.3% growth [11] Valuation Metrics - The industry is currently trading at a forward 12-month P/E ratio of 21.15X, below the S&P 500's 23.32X and the sector's 28.93X [14] Company Highlights - **Netlist (NLST)**: Experienced a 44% sequential revenue increase to $41.7 million, driven by DDR5 demand, and is pursuing legal actions against Samsung and Micron for patent infringements [20][21] - **Pure Storage (PSTG)**: Expanded its Flash portfolio and reported strong demand for its products, with a Zacks Rank of 3 and a 71.6% stock gain over the past year [25][27] - **NetApp (NTAP)**: Benefiting from demand for all-flash arrays and cloud storage solutions, with Keystone storage-as-a-service revenues growing 80% year-over-year [32][33]
PFE vs. AZN: Which Cancer-Focused Drug Giant Is the Better Pick?
ZACKS· 2025-09-19 13:30
Core Insights - Pfizer (PFE) and AstraZeneca (AZN) are leading players in the oncology sector, with significant revenue contributions from this area [1][2] - Pfizer's oncology sales account for over 25% of total revenues, growing by 9% in H1 2025, while AstraZeneca's oncology sales represent around 43% of total revenues, increasing by 16% in the same period [1][2][11] - Both companies have robust R&D pipelines that are expected to drive future growth [3] Pfizer Overview - Pfizer's acquisition of Seagen in 2023 has bolstered its oncology position [4] - Non-COVID operational revenues are improving, with key products generating $4.7 billion in H1 2025, a 15% operational increase year-over-year [5] - Pfizer anticipates $7.7 billion in cost savings by the end of 2027 and projects a revenue CAGR of approximately 6% from 2025 to 2030 [6] - Challenges include potential declines in COVID-related sales and significant patent expirations expected between 2026 and 2030, impacting key products [7][8] AstraZeneca Overview - AstraZeneca's portfolio includes several blockbuster drugs, with sales exceeding $1 billion, contributing to strong revenue growth [9] - The company plans to launch 20 new medicines by 2030, targeting $80 billion in total revenues [12] - AstraZeneca's newer drugs are contributing positively to top-line growth in 2025 [10] - Challenges include the impact of Medicare Part D redesign on key drug sales and competition from generics and biosimilars [13][14] Financial Estimates and Performance - Pfizer's 2025 sales and EPS estimates indicate modest growth of 0.3% and 1.0%, respectively, with EPS estimates rising from $3.05 to $3.14 [15] - AstraZeneca's 2025 sales and EPS estimates suggest stronger growth of 8.4% and 11.4%, with EPS estimates increasing from $4.50 to $4.58 [16] - Year-to-date stock performance shows Pfizer declining by 9.0%, while AstraZeneca has increased by 17.6% [18] Valuation and Dividend Yield - AstraZeneca's shares trade at a forward P/E ratio of 15.44, while Pfizer's are at 7.79, indicating a more attractive valuation for Pfizer [19] - Pfizer offers a higher dividend yield of 7.1% compared to AstraZeneca's 2.4% [22] - AstraZeneca has a higher return on equity at 32.8% versus Pfizer's 21.4% [22] Investment Outlook - Both companies are rated with a Zacks Rank 3 (Hold), making it challenging to determine a clear investment preference [23] - AstraZeneca is viewed as a safer investment due to its efficient profitability and clearer growth targets, despite Pfizer's attractive valuation and dividend yield [25]
Is the Options Market Predicting a Spike in Invitation Home Stock?
ZACKS· 2025-09-19 13:30
Group 1 - Investors in Invitation Homes Inc. should monitor the stock closely due to significant movements in the options market, particularly the Oct 17, 2025 $17.50 Call which has high implied volatility [1] - Implied volatility indicates the market's expectation of future price movement, suggesting that investors anticipate a significant change in the stock's price, potentially due to an upcoming event [2] - Invitation Homes currently holds a Zacks Rank 3 (Hold) in the REIT and Equity Trust - Residential industry, which is in the bottom 29% of the Zacks Industry Rank, with no analysts increasing earnings estimates for the current quarter [3] Group 2 - The high implied volatility for Invitation Homes may indicate a developing trading opportunity, as options traders often seek to sell premium on such options to capture decay [4]
The New Baseline ‘Destiny 2’ Playercount Is A 50% Drop, So Far
Forbes· 2025-09-19 13:30
Destiny 2BungieIt has not been a great week for Destiny 2, which has come after a not great couple months for Destiny, now in its Edge of Fate-initiated Portal-based era. We all knew that there would be less Destiny 2 content produced in the wake of The Final Shape, Bungie was pretty clear about the direction that was going with two smaller expansions a year and no more true seasons or episodes. The question, however, was what the new baseline was going to be for Destiny 2 going forward, and I think enough ...
How You Can Earn $50K Without Quitting Your Job
Invested Wallet· 2025-09-19 13:30
Group 1: Passive Income Streams - Multiple streams of passive income can enhance overall earnings and provide financial stability [1] - Diversifying income reduces reliance on a single job and allows for a more flexible lifestyle [1] Group 2: Vending Machines - Strategic placement of vending machines in high-traffic areas like medical centers and universities can yield significant profits [2] - Initial investment of approximately $10,000 for five machines, with ROI typically within 12-18 months [2] Group 3: Automated Car Wash Systems - Automated car washes can handle over 50 cars daily with minimal supervision, focusing on busy intersections [6] - Maintenance checks are required twice a month, allowing owners to concentrate on expansion [6] Group 4: White-Label Mobile Apps - Development of customizable mobile apps for small businesses can generate $2,000-5,000 per app, with ongoing maintenance fees of $200-500 monthly [10] Group 5: Self-Storage Facilities - Self-storage facilities can generate monthly revenue of $8,000-15,000 with an initial investment of $500,000 to $1,000,000 [12] - Operations can be streamlined with digital contracts and automated payment systems [12] Group 6: Digital Planners and Templates - Creating and selling digital planners can yield over $10,000 monthly for top creators [15] Group 7: EV Charging Stations - EV charging stations can generate $300-600 daily in busy areas, with installation costs between $50,000-80,000 [19] - Government incentives can cover 30-50% of installation costs [19] Group 8: Data Center REITs - Data center REITs offer monthly dividend payments ranging from 3% to 6% annually, with total returns of 15-20% over the past five years [17] Group 9: Stock Video Footage - High-quality stock video clips can sell for $30-150, with some videographers earning $3,000-5,000 monthly [21] Group 10: Mineral Rights and Royalties - Mineral rights ownership can yield average annual returns of $4,000-12,000 per acre [23] Group 11: Laundromat Franchises - Card-operated laundromats can operate 24/7, reducing staffing needs and allowing for remote monitoring [25] Group 12: Billboard Advertising - Digital billboards can generate 3-4 times more revenue than traditional ones, with monthly lease income ranging from $1,000-4,000 [29]
AstraZeneca: Consistent Growth And Upcoming Catalysts Make This A Buy
Seeking Alpha· 2025-09-19 13:30
The Cambridge, UK-based AstraZeneca PLC ( AZN ) was founded in 1999 as an amalgamation of the pharmaceutical companies Zeneca Group, based in Britain, and Astra AB, from Sweden. The company’s primary listing is in the UK (I have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believe the key to c ...
Inflection Resources Announces CFO Update
Thenewswire· 2025-09-19 13:30
 Vancouver, British Columbia - TheNewswire - September 19, 2025:  Inflection Resources Ltd. (CSE: AUCU / OTCQB: AUCUF / FSE: 5VJ) (the "Company" or "Inflection") is pleased to announce the appointment of Mr. David Cross as Chief Financial Officer of the Company effective immediately. Mr. Cross is a Chartered Professional Accountant ("CPA") who brings 28 years of accounting experience, primarily in the mining and mineral exploration sector.  Mr. Cross is a co-founder of Cross Davis & Company, a CPA firm tha ...
Comstock Welcomes The Venardos Circus to Loudoun Station's Summerbration
Businesswire· 2025-09-19 13:30
RESTON, Va.--(BUSINESS WIRE)--Comstock Holding Companies, Inc. (Nasdaq: CHCI) ("Comstock†or the "Company†), a leading asset manager, developer, and operator of mixed-use and transit-oriented properties in the Washington, D.C. region, announced today that The Venardos Circus, a Broadway-style, animal-free circus experience, is now is now running at Loudoun Station with performances through September 28. Founded by former Ringling Bros. Ringmaster Kevin Venardos, The Venardos Circus blends world. ...